Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16312822 | 0.77 | SIGMAR1 (0.61) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL12487706 | 0.74 | SIGMAR1 (0.57) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL30624762 | 0.72 | SIGMAR1 (0.71) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL21243273 | 0.72 | SIGMAR1 (0.73) | SIGMAR1TAAR1SLC18A2MEN1KMT2A | |
| SCHEMBL9134313 | 0.72 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2CYP1A2CYP3A4 | |
| SCHEMBL711506 | 0.72 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2CYP1A2CYP3A4 | |
| Etilamfetamine SCHEMBL309802 | 0.71 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2CYP1A2CYP3A4 | |
| Etilamfetamine SCHEMBL27754453 | 0.71 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2CYP1A2CYP3A4 | |
| Etilamfetamine SCHEMBL16866783 | 0.71 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2CYP1A2CYP3A4 | |
| Etilamfetamine SCHEMBL162316 | 0.71 | SIGMAR1 (1.00) | SIGMAR1TAAR1SLC18A2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | MINDSET PHARMA INC. (CA) | 2024-10-17 | — | — | US | disclosed |
| CN-118234491-A | Hallucinogen-fatty acid combinations | 明德赛特制药公司 | 2024-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | FAAH, HTR5A, FAAH2 | SIGMAR1 195/4885TAAR1 47/4885SLC18A2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.